Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury

Vimala N. Bharadwaj, Rachel K. Rowe, Jordan Harrison, Chen Wu, Trent R Anderson, Jonathan Lifshitz, P. David Adelson, Vikram D. Kodibagkar, Sarah E. Stabenfeldt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

Original languageEnglish (US)
Pages (from-to)2155-2166
Number of pages12
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number7
DOIs
StatePublished - Oct 1 2018

Fingerprint

Nanoparticles
Brain Injuries
Brain
Percussion
Craniocerebral Trauma
Wounds and Injuries
Fluids
Brain models
Pathology
Microscopy
Permeability
Microscopic examination
Animals
Animal Models
Perfusion
Traumatic Brain Injury

Keywords

  • Blood-brain barrier
  • Drug delivery
  • Fluid percussion injury
  • Mild closed head injury
  • Nanoparticles
  • Optimal therapeutic window
  • Pharmacodynamics
  • Traumatic brain injury

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury. / Bharadwaj, Vimala N.; Rowe, Rachel K.; Harrison, Jordan; Wu, Chen; Anderson, Trent R; Lifshitz, Jonathan; Adelson, P. David; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 7, 01.10.2018, p. 2155-2166.

Research output: Contribution to journalArticle

Bharadwaj, Vimala N. ; Rowe, Rachel K. ; Harrison, Jordan ; Wu, Chen ; Anderson, Trent R ; Lifshitz, Jonathan ; Adelson, P. David ; Kodibagkar, Vikram D. ; Stabenfeldt, Sarah E. / Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 7. pp. 2155-2166.
@article{a089988022b8466cbf572ff5d36728f0,
title = "Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury",
abstract = "Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.",
keywords = "Blood-brain barrier, Drug delivery, Fluid percussion injury, Mild closed head injury, Nanoparticles, Optimal therapeutic window, Pharmacodynamics, Traumatic brain injury",
author = "Bharadwaj, {Vimala N.} and Rowe, {Rachel K.} and Jordan Harrison and Chen Wu and Anderson, {Trent R} and Jonathan Lifshitz and Adelson, {P. David} and Kodibagkar, {Vikram D.} and Stabenfeldt, {Sarah E.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.nano.2018.06.004",
language = "English (US)",
volume = "14",
pages = "2155--2166",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Blood–brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury

AU - Bharadwaj, Vimala N.

AU - Rowe, Rachel K.

AU - Harrison, Jordan

AU - Wu, Chen

AU - Anderson, Trent R

AU - Lifshitz, Jonathan

AU - Adelson, P. David

AU - Kodibagkar, Vikram D.

AU - Stabenfeldt, Sarah E.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

AB - Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood–brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.

KW - Blood-brain barrier

KW - Drug delivery

KW - Fluid percussion injury

KW - Mild closed head injury

KW - Nanoparticles

KW - Optimal therapeutic window

KW - Pharmacodynamics

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85050717849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050717849&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.06.004

DO - 10.1016/j.nano.2018.06.004

M3 - Article

VL - 14

SP - 2155

EP - 2166

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 7

ER -